

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 19, 2012**

**LANTHEUS MEDICAL IMAGING, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**333-169785**

(Commission File Number)

**51-0396366**

(IRS Employer Identification No.)

**331 Treble Cove Road, North Billerica, MA 01862**

(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: **(978) 671-8001**

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**Item 1.01 Entry into a Material Definitive Agreement.**

*Nordion Amendment No. 2*

On October 19, 2012, the registrant, Lantheus Medical Imaging, Inc. (the “Company”), entered into Amendment No. 2 (the “Amendment”), effective as of October 15, 2012, to the Molybdenum-99 Purchase & Supply Agreement, dated as of April 1, 2010 (as amended, the “Agreement”), between the Company and Nordion (Canada) Inc. (formerly known as MDS Nordion, a division of MDS (Canada) Inc.) (“Nordion”). The Amendment extends the contract term of the Agreement from December 31, 2013 to December 31, 2015 and modifies the Company’s purchase requirements and supply fees. The Agreement allows for termination upon the occurrence of certain events, including, but not limited to, certain cost increases experienced by Nordion (but in such event not earlier than October 1, 2014), failure to comply with material obligations by either party, bankruptcy of either party or force majeure events.

A copy of the press release announcing the Amendment is filed herewith as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release, dated October 22, 2012, announcing the Amendment of the Agreement between the Company and Nordion

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LANTHEUS MEDICAL IMAGING, INC.

By: /s/ Michael P. Duffy  
Name: Michael P. Duffy  
Title: Vice President and General Counsel

Date: October 22, 2012

**EXHIBIT LIST**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release, dated October 22, 2012, announcing the Amendment of the Agreement between the Company and Nordion



331 Treble Cove Road  
North Billerica, MA 01862

800.362.2668  
www.lantheus.com

**CONTACTS:**

**Lantheus Medical Imaging**

Linda Lennox  
978-671-8854

Meara Murphy  
978-671-8508

**Pure Communications**

Michele Rozen  
617-730-8284

**FOR IMMEDIATE RELEASE**

**Lantheus Medical Imaging and Nordion  
Extend Molybdenum-99 Supply Contract through 2015**

**No. BILLERICA, Mass. (October 22, 2012)** — Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that it has extended its contract with Nordion to supply molybdenum-99 (Mo-99) for use in its TechneLite® (Technetium Tc 99m Generator) generators. Mo-99 is the parent isotope of technetium-99m (Tc-99m), the medical radioisotope most widely used in nuclear medicine diagnostic imaging tests.

“As a leading provider of radioisotope generators, securing the supply of critical isotopes such as Mo-99 is of prime importance to the success of our business,” said Don Kiepert, President and Chief Executive Officer of Lantheus Medical Imaging. “Our amended contract with Nordion further solidifies our globally diversified sourcing of Mo-99, which reinforces our ongoing commitment to provide a stable, balanced and reliable supply to our customers.”

“One of Nordion’s key priorities is providing a continuous supply of medical isotopes to meet the needs of the global medical community, and the extension of our Mo-99 supply contract with Lantheus further advances this objective,” said Steve West, Chief Executive Officer, Nordion. “We value the ongoing relationship with Lantheus and are focused on identifying new isotope sources to provide a stable supply chain for our partners worldwide.”

**About Molybdenum-99 and Technetium-99m**

Mo-99 is the parent isotope of technetium-99m (Tc-99m), which is the radioisotope most widely used for nuclear medicine diagnostic imaging tests. Tc-99m is a critical component of many medical tests, including scans of the heart, brain, kidneys and some types of tumors. Tc-99m is used in Lantheus Medical Imaging’s TechneLite® generators, which are distributed to hospitals

and radiopharmacies as a source of Tc-99m for diagnostic imaging procedures. Tc-99m is also used with Cardiolite® (Kit for the Preparation of Technetium Tc 99m Sestamibi for Injection), the most successful radiopharmaceutical agent, which has been used to image more than 40 million patients.(1) In diagnostic use, Tc-99m is attached to a specific molecule and injected into the patient, where it emits gamma radiation that can be used to produce an image of the region.

**About Lantheus Medical Imaging, Inc.**

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company's proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallos Chloride TI 201 Injection). Lantheus has approximately 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit [www.lantheus.com](http://www.lantheus.com).

**About Nordion Inc.**

Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of medical isotopes, targeted therapies and sterilization technologies that benefit the lives of millions of people in more than 60 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has approximately 500 highly skilled employees in four locations. Find out more at [www.nordion.com](http://www.nordion.com) and follow us at <http://twitter.com/NordionInc>.

**Safe Harbor for Forward-Looking and Cautionary Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that may be described from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company

undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

###

**References**

1. ©AMR Imaging Market Guides — US (1990-2011). AMR/Arlington Medical Resources, LLC. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission.